OncoTherapy Science, Inc.
4564
Rank in Stocks
#23264
OncoTherapy Science, Inc. engages in research and development of anti-body... OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Share Price
$0.10760413
Last synced: 2026-11-10
Market Cap
$43.93M
Change (1 day)
6.25%
Change (1 year)
-30.93%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade OncoTherapy Science, Inc. (4564)
Category
Healthcare
Operating Margin for OncoTherapy Science, Inc. (4564)
Operating Margin as of November 2026 TTM: -106.36%
According to OncoTherapy Science, Inc.'s latest financial reports, its current operating margin (TTM) is -106.36%. At the end of 2025 the company had an operating margin of -106.38%.
Operating Margin history for OncoTherapy Science, Inc. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -106.36% | -0.02% |
| 2025 | -106.38% | -42.09% |
| 2024 | -183.70% | 88.43% |
| 2023 | -97.49% | -45.21% |
| 2022 | -177.92% | -63.89% |
| 2021 | -492.65% | -28.86% |
| 2020 | -692.46% | -34.22% |
| 2019 | -1,052.72% | -25.59% |
| 2018 | -1,414.71% | 34.99% |
| 2017 | -1,047.98% | -6.17% |
| 2016 | -1,116.85% | 338.19% |
| 2015 | -254.88% | -31.48% |
| 2014 | -371.98% | 994.70% |
| 2013 | -33.98% | -278.56% |
| 2012 | 19.03% | 356.35% |
| 2011 | 4.17% | -31.19% |
| 2010 | 6.06% | 639.02% |
| 2009 | 0.82% | -104.20% |
| 2008 | -19.54% | -88.34% |
| 2007 | -167.64% | 134.26% |
| 2006 | -71.56% | -3,323.42% |
| 2005 | 2.22% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.36% |
US
|
|
| -149.01% | -98.60% |
US
|
|
| 25.57% | -100.24% |
AU
|
|
| 31.23% | -100.29% |
BE
|
|
| 29.35% | -100.28% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about OncoTherapy Science, Inc.'s operating margin
What is OncoTherapy Science, Inc.'s operating margin?
OncoTherapy Science, Inc.'s operating margin is -106.36%, as of Nov 2026.
What was OncoTherapy Science, Inc.'s operating margin in 2025?
In 2025, OncoTherapy Science, Inc.'s operating margin was -106.38%, compared with -183.70% in 2024.
How has OncoTherapy Science, Inc.'s operating margin changed since 2020?
From 2020 to 2025, OncoTherapy Science, Inc.'s operating margin was highest in 2023 (-97.49%) and lowest in 2020 (-692.46%).
How does OncoTherapy Science, Inc.'s operating margin compare with similar companies?
OncoTherapy Science, Inc.'s operating margin (-106.36%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.